Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative

Archives of Internal Medicine

Volumn 172, Issue 2, 2012, Pages 144-152

  Culver, Annie L ^a   Ockene, Ira S ^b   Balasubramanian, Raji ^c   Olendzki, Barbara C ^b   Sepavich, Deidre M ^b   Wactawski Wende, Jean ^d   Manson, JoAnn E ^e   Qiao, Yongxia ^b,f   Liu, Simin ^g   Merriam, Philip A ^b   Rahilly Tierny, Catherine ^e,h   Thomas, Fridtjof ⁱ   Berger, Jeffrey S ^j   Ockene, Judith K ^b   Curb, J David ^k   Ma, Yunsheng ^b  

^a Rochester Methodist Hospital   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h VA BOSTON HEALTHCARE SYSTEM   (United States)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^j NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY OF HAWAII   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; ETHNICITY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; WOMEN'S HEALTH;

AGED; CARDIOVASCULAR DISEASES; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; POSTMENOPAUSE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; UNITED STATES;

EID: 84862908066     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.625     Document Type: Article

References (45)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
2. Grundy SM, Cleeman JI, Merz CN, et al National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239. (Pubitemid 38924592)
3. Pedersen TR, Kjekshus J, Berg K, et al Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler Suppl. 2004;5(3):81-87.
4. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
5. Sacks FM, Pfeffer MA, Moye LA, et al Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001-1009. (Pubitemid 26338729)
6. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.
7. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42(9):1208-1215.
8. Crestor prescription information. http://www1.astrazeneca-us.com/pi/ crestor.pdf. Accessed November 18, 2011.
9. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742.
10. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated highsensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121(9):1069-1077.
11. Yokote K, Saito Y; CHIBA. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb. 2009;16(3):297-298.
12. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129-2140.
13. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57(14):1535-1545.
14. Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87(1):98-107.
15. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA. 2011;305(8):822-823.
16. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109-124.
17. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305(24):2556-2564.
18. Liu S, Tinker L, Song Y, et al. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med. 2007;167(15):1676-1685. (Pubitemid 47280350)
19. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006; 295(11):1288-1299.
20. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61-109.
21. Ritenbaugh C, Patterson RE, Chlebowski RT, et al. The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13(9)(suppl):S87-S97. (Pubitemid 37324178)
22. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13(9)(suppl):S78-S86. (Pubitemid 37324177)
23. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol. 2003;13(9)(suppl):S107-S121. (Pubitemid 37324180)
24. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation. 2004;110(7):886-892. (Pubitemid 39096019)
25. Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3- methylglutarylcoenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol. 2002;42(8):835-845. (Pubitemid 34803847)
26. de Boer IH, Tinker LF, Connelly S, et al Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care. 2008;31(4):701-707.
27. Bonds DE, Lasser N, Qi L, et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia. 2006;49(3):459-468. (Pubitemid 43277868)
28. Margolis KL, Bonds DE, Rodabough RJ, et al Women's Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004;47(7):1175-1187. (Pubitemid 39093314)
29. Margolis KL, Lihong Qi, Brzyski R, et al; Women Health Initiative Investigators. Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials. 2008; 5(3):240-247.
30. Heckbert SR, Kooperberg C, Safford MM, et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol. 2004;160(12):1152-1158. (Pubitemid 39628055)
31. Conen D, Ridker PM, Mora S, Buring JE, Glynn RJ. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J. 2007; 28(23):2937-2943. (Pubitemid 350233022)
32. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol. 1999;9(3):178-187. (Pubitemid 29144458)
33. McTiernan A, Kooperberg C, White E, et al Women's Health Initiative Cohort Study. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA. 2003;290(10): 1331-1336. (Pubitemid 37442629)
34. Song Y, Manson JE, Tinker L, et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. Diabetes Care. 2007;30(7):1747-1752. (Pubitemid 47036347)
35. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8, pt 2):757-763. (Pubitemid 27446562)
36. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924-1929.
37. Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring). 2010;18(3):604-610.
38. Biggs ML, Mukamal KJ, Luchsinger JA, et al. Association between adiposity in midlife and older age and risk of diabetes in older adults. JAMA. 2010;303(24):2504-2512.
39. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
40. Brunzell JD, Davidson M, Furberg CD, et al American Diabetes Association; American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-822.
41. Oksanen T, Kivimäki M, Pentti J, Virtanen M, Klaukka T, Vahtera J. Self-report as an indicator of incident disease. Ann Epidemiol. 2010;20(7):547-554.
42. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol. 2004;57(10):1096-1103. (Pubitemid 39446649)
43. Simpson RJ Jr, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010;4(6):462-471.
44. American Diabetes Association. Standards of medical care in diabetes: 2011. Diabetes Care. 2011;34(suppl 1):S11-S61.
45. Cholesterol Treatment Trialists' Collaboration (CTT). Accessed September 30, 2011. http://www.ctsu.ox.ac.uk/projects/ctt.